AG-13958

N/A

Report date: 2022/07/04 19:38:02

NME

Base Information

Drug NameAG-13958

Drug Alias NameAG-13958AG-013958

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionPlatelet-derived growth factor receptor inhibitorsVascular endothelial growth factor receptor 2 antagonistsVascular endothelial growth factor A inhibitors

TargetsPlatelet-derived growth factor receptorVascular endothelial growth factor receptor 2Vascular endothelial growth factor A

Therapy Area/IndicationsMacular Degeneration

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesNetherlandsAustralia +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsMacular Degeneration

Other Information

ATC CodeN/A